Novo says CagriSema cut women's weight 25% in REDEFINE 1 analysis
The ad hoc analysis lands ahead of a December FDA decision, after the trial's overall 20.4% weight loss fell short of company expectations.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 21 07:40 ETSource: pharmaphorum
The wire
- 01An ad hoc analysis of REDEFINE 1 found women on the cagrilintide-semaglutide combination lost an average 25% of body weight at 68 weeks versus 3% on placebo, with reduced waist circumference.
- 02Novo is positioning CagriSema as the first amylin analogue plus GLP-1 receptor agonist for weight management as Wegovy loses ground to Lilly's Zepbound and faces early-2030s patent expiry.
- 03Results were strongest in premenopausal women at 26.7%, versus 24.8% perimenopausal and 23.1% postmenopausal; the analysis was not prespecified, and REDEFINE 4 failed to show non-inferiority to Zepbound.
From the source
Read at pharmaphorum.comCagriSema helps women lose 25% of their weight in study
Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women as it waits for an approval decision from the FDA in December.
